A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients with Performance Anxiety

Brief description of study

Performance anxiety is a type of anxiety disorder characterized by excessive fear, discomfort, and self-consciousness in a variety of social situations related to performing in front of others such as public speaking. The purpose of the study is to evaluate the effect of an investigational drug called VQW-765 on symptoms associated with performance anxiety and to assess the safety of VQW-765.


Clinical Study Identifier: s20-01876
ClinicalTrials.gov Identifier: NCT04800237
Principal Investigator: Naomi M. Simon.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.